Integrated FDG-PET/CT vs. standard radiological examinations: Comparison of capability for assessment of postoperative recurrence in non-small cell lung cancer patients

European Journal of Radiology

Volumn 74, Issue 3, 2010, Pages 458-464

  Takenaka, Daisuke ^a   Ohno, Yoshiharu ^a   Koyama, Hisanobu ^a   Nogami, Munenobu ^b   Onishi, Yumiko ^a   Matsumoto, Keiko ^a   Matsumoto, Sumiaki ^a,c   Yoshikawa, Takeshi ^a   Sugimura, Kazuro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

FDG; Lung cancer; PET CT; Recurrence; Surgery

Indexed keywords

AREA UNDER THE CURVES; DIAGNOSTIC CAPABILITIES; FDG; LUNG CANCER; MCNEMAR; MEAN AGES; NON SMALL CELL LUNG CANCER; ROC ANALYSIS; SCORING SYSTEMS; STATISTICALLY SIGNIFICANT DIFFERENCE; WHOLE-BODY;

BIOLOGICAL ORGANS; RADIOLOGY; SURGERY;

STANDARDS;

FLUORODEOXYGLUCOSE;

AGED; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER RECURRENCE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE DURATION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MCNEMAR TEST; OBSERVER VARIATION; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROBABILITY; RADIODIAGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

CARCINOMA, NON-SMALL-CELL LUNG; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SUBTRACTION TECHNIQUE; SYSTEMS INTEGRATION; TOMOGRAPHY, X-RAY COMPUTED; X-RAY FILM;

EID: 77952882160     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2009.03.007     Document Type: Article

References (37)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. Cancer J Clin 55 (2005) 74-108
2. Melamed M.R., Flehinger B.J., and Zaman M.B. Impact of early detection on the clinical course of lung cancer. Surg Clin North Am 67 (1987) 909-924
3. Deslauriers J. Current surgical treatment of nonsmall cell lung cancer 2001. Eur Respir J 35 (2002) S61-S70
4. Krupnick A.S., Kreisel D., Hope A., Bradley J., Govindan R., and Meyers B. Recent advances and future perspectives in the management of lung cancer. Curr Probl Surg 42 (2005) 540-610
5. Martini N., Bains M.S., Burt M.E., et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 109 (1995) 120-129
6. al-Kattan K., Sepsas E., Fountain S.W., and Townsend E.R. Disease recurrence after resection for stage I lung cancer. Eur J Cardiothorac Surg 12 (1997) 380-384
7. Martin J., Ginsberg R.J., Venkatraman E.S., et al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol 20 (2002) 1989-1995
8. Mortelmans L., Vanhaecke J., Lesaffre E., et al. Evaluation of the effect of thrombolytic treatment on infarct size and left ventricular function by enzymatic, scintigraphic, and angiographic methods. The European Cooperative Study Group for Recombinant Tissue Type Plasminogen Activator. Am Heart J 119 (1990) 1231-1237
9. Mortelmans L., Nuyts J., Scheys I., et al. A new quantitative method for the analysis of cardiac perfusion tomography (SPET): validation in post-infarct patients treated with thrombolytic therapy. Eur J Nucl Med 20 (1993) 1193-1200
10. Hustinx R., Benard F., and Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 32 (2002) 35-46
11. Lardinois D., Weder W., Hany T.F., et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348 (2003) 2500-2507
12. Cerfolio R.J., Ojha B., Bryant A.S., Raghuveer V., Mountz J.M., and Bartolucci A.A. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 78 (2004) 1017-1023
13. Halpern B.S., Schiepers C., Weber W.A., et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 128 (2005) 2289-2297
14. Nakamoto Y., Senda M., Okada T., et al. Software-based fusion of PET and CT images for suspected recurrent lung cancer. Mol Imaging Biol 10 (2008) 147-153
15. Svanholm H., Starklint H., Gundersen H.J., Fabricius J., Barlebo H., and Olsen S. Reproducibility of histomorphologic diagnoses with special reference to the kappa statistic. APMIS 97 (1989) 689-698
16. Aquino S.L., Kuester L.B., Muse V.V., Halpern E.F., and Fischman A.J. Accuracy of transmission CT and FDG-PET in the detection of small pulmonary nodules with integrated PET/CT. Eur J Nucl Med Mol Imaging 33 (2006) 692-696
17. Meirelles G.S., Erdi Y.E., Nehmeh S.A., et al. Deep-inspiration breath-hold PET/CT: clinical findings with a new technique for detection and characterization of thoracic lesions. J Nucl Med 48 (2007) 712-719
18. Patz Jr. E.F., Lowe V.J., Hoffman J.M., et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 188 (1993) 487-490
19. Dewan N.A., Gupta N.C., Redepenning L.S., Phalen J.J., and Frick M.P. Diagnostic efficiency of PET-FDG imaging in solitary pulmonary nodules. Chest 104 (1993) 997-1002
20. DeVita Jr. V.T., Young R.C., and Canellos G.P. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 35 (1975) 98-110
21. Liotta L.A., Kleinerman J., and Saidel G.M. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34 (1974) 997-1004
22. Rak J.W., St Croix B.D., and Kerbel R.S. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 6 (1995) 3-18
23. Rohren E.M., Provenzale J.M., Barboriak D.P., and Coleman R.E. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology 226 (2003) 181-187
24. Griffeth L.K., Rich K.M., Dehdashti F., et al. Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology 186 (1993) 37-44
25. Rohren E.M., Turkington T.G., and Coleman R.E. Clinical applications of PET in oncology. Radiology 231 (2004) 305-332
26. Beyer T., Antoch G., Bockisch A., and Stattaus J. Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT. J Nucl Med 46 (2005) 429-435
27. Berthelsen A.K., Holm S., Loft A., Klausen T.L., Andersen F., and Højgaard L. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 32 (2005) 1167-1175
28. Mawlawi O., Erasmus J.J., Munden R.F., et al. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. Am J Roentgenol 186 (2006) 308-319
29. Brechtel K., Klein M., Vogel M., et al. Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging. J Nucl Med 47 (2006) 470-476
30. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996-3018.
31. Sause W.T., Byhardt R.W., Curran Jr. W.J., et al. Follow-up of non-small cell lung cancer. American College of Radiology. ACR Appropriateness Criteria. Radiology 215 (2000) S1363-S1372
32. Colice G.L., Rubins J., Unger M., and American College of Chest Physicians. Follow-up and surveillance of the lung cancer patient following curative-intent therapy. Chest 123 (2003) S272-S283
33. Rubins J., Unger M., Colice G.L., and American College of Chest Physicians. Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 132 (2007) S355-S367
34. Hicks R.J., Kalff V., MacManus M.P., et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 42 (2001) 1605-1613
35. Keidar Z., Haim N., Guralnik L., et al. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 45 (2004) 1640-1646
36. Hellwig D., Gröschel A., Graeter T.P., et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 33 (2006) 13-21
37. Fletcher J.W., Djulbegovic B., Soares H.P., et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 49 (2008) 480-508